组蛋白去乙酰化酶抑制剂治疗卵巢癌的研究进展

Research Progress in Histone Deacetylase Inhibitors Associated with Ovarian Cancer

卵巢癌是致死率最高的妇科恶性肿瘤,其发病机制的探讨是肿瘤研究领域的难点,近年研究发现卵巢癌的发生与表观遗传学改变密切相关,针对影响表观遗传的重要分子靶标组蛋白去乙酰化酶的研究成为新热点。组蛋白去乙酰化酶抑制剂(HDAC Is)可以明显地抑制卵巢癌细胞生长,诱导细胞周期阻滞、分化和凋亡,抑制卵巢癌相关致癌基因的表达,具有抗肿瘤活性且无明显不良反应,提示HDACIs为卵巢癌的治疗提供了一种新策略。

Ovarian cancer has the highest mortality among gynecological malignancies. The pathogenesis of ovarian cancer has been always challenging. Recent studies show that ovarian cancer gene mutations are assoicated with epigenetic changes. The research on histone deacetylase, an important molecular target of epi- genetic changes,has become increasingly recognized. Previous studies show that histone deacetylase inhlbitors （HDACIs） can significantly inhibit the growth of ovarian cancer,induce cell cycle arrest, differentiation, and apoptosis,inhibit ovarian cancer-related oncogene expressions, and have anti-tumor activity without obvious side effects, suggesting the role of HDACIs as a new strategy in the treatment of ovarian cancer.